Welcome to our dedicated page for Longduoduo Co SEC filings (Ticker: LDDD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Longduoduo Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Longduoduo Co's regulatory disclosures and financial reporting.
Longduoduo Co., Ltd. operates preventive healthcare services in China through a network of third-party providers and consolidated subsidiaries. The company reported positive net income of $492,260 for the year ended June 30, 2025, down from $1,363,278 a year earlier, and operating income declined from $2,026,141 to $552,679. Advertising and promotion expenses decreased to $1,942,661 from $3,338,737, and cash in excess of insured amounts was $1,130,547 at June 30, 2025. The company completed corporate reorganizations and acquisitions of multiple subsidiaries (including LDD, Julong, Yihua) and completed a 1-for-10 reverse stock split in September 2023, leaving 30,015,036 shares outstanding. Significant disclosures include a 100% valuation allowance on deferred tax assets and identified deficiencies in internal controls and accounting expertise.
